| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a05269239abfa121305bc79cc1291a1a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1016 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a6191a86d3e4b209abbcd044abd6dfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6111cce17c6c60ec64fab0dfdc8043d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53b8d250e27c2222b0dbce9abf665470
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1401d99a6b286cf9ec9251c9574615e1 |
| publicationDate |
2020-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10836792-B2 |
| titleOfInvention |
Retro-inverso peptide inhibitors of cell migration, extracellular matrix and endothelial invasion by tumor cells |
| abstract |
The present invention discloses retro-inverso peptides and pharmaceutical composition containing them. The peptides of the invention prevent key events occurring during the metastatic process, i.e. invasion of the extracellular matrix, formation of a capillary network, and the entry into bloodstream. They are therefore useful in the treatment of diseases and conditions that are sustained by an increase of cell motility, cell invasion, and/or angiogenesis, such as tumors and chronic inflammation. |
| priorityDate |
2016-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |